HK1088318A1 - Pyrrole-2, 5-dithione derivatives as liver x receptor modulators - Google Patents

Pyrrole-2, 5-dithione derivatives as liver x receptor modulators

Info

Publication number
HK1088318A1
HK1088318A1 HK06108722.2A HK06108722A HK1088318A1 HK 1088318 A1 HK1088318 A1 HK 1088318A1 HK 06108722 A HK06108722 A HK 06108722A HK 1088318 A1 HK1088318 A1 HK 1088318A1
Authority
HK
Hong Kong
Prior art keywords
pyrrole
liver
receptor modulators
dithione
derivatives
Prior art date
Application number
HK06108722.2A
Other languages
English (en)
Inventor
Patrik Holm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1088318A1 publication Critical patent/HK1088318A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
HK06108722.2A 2003-07-11 2006-08-07 Pyrrole-2, 5-dithione derivatives as liver x receptor modulators HK1088318A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316237.7A GB0316237D0 (en) 2003-07-11 2003-07-11 Therapeutic agents
PCT/SE2004/001115 WO2005005416A1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dithione derivatives as liver x receptor modulators

Publications (1)

Publication Number Publication Date
HK1088318A1 true HK1088318A1 (en) 2006-11-03

Family

ID=27741986

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06108722.2A HK1088318A1 (en) 2003-07-11 2006-08-07 Pyrrole-2, 5-dithione derivatives as liver x receptor modulators

Country Status (26)

Country Link
US (1) US20060189663A1 (ru)
EP (1) EP1646625B1 (ru)
JP (1) JP2007521313A (ru)
KR (1) KR20060034284A (ru)
CN (1) CN100478340C (ru)
AR (1) AR045720A1 (ru)
AT (1) ATE399776T1 (ru)
AU (1) AU2004256000B2 (ru)
BR (1) BRPI0412479A (ru)
CA (1) CA2532068A1 (ru)
CO (1) CO5640134A2 (ru)
DE (1) DE602004014772D1 (ru)
ES (1) ES2308205T3 (ru)
GB (1) GB0316237D0 (ru)
HK (1) HK1088318A1 (ru)
IL (1) IL172759A0 (ru)
IS (1) IS8291A (ru)
MX (1) MXPA06000447A (ru)
NO (1) NO20060080L (ru)
RU (1) RU2006102129A (ru)
SA (1) SA04250203B1 (ru)
TW (1) TW200507836A (ru)
UA (1) UA82108C2 (ru)
UY (1) UY28407A1 (ru)
WO (1) WO2005005416A1 (ru)
ZA (1) ZA200600229B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
MX2007008370A (es) 2005-01-10 2007-08-21 Astrazeneca Ab Derivados de 1,1-dioxidos de isotiazol-3 (2h) -ona como moduladores del receptor del higado x.
SE0500058D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
ES2438739T3 (es) * 2005-06-28 2014-01-20 Daiichi Sankyo Company, Limited Procedimiento de prueba de ligando LXR
AU2007286807B2 (en) 2006-08-21 2013-03-21 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
WO2008046014A1 (en) 2006-10-12 2008-04-17 Remedy Pharmaceuticals, Inc. Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors
WO2008103818A1 (en) * 2007-02-21 2008-08-28 University Of Louisville Research Foundation Therapeutic cotinine compositions
ES2638977T3 (es) 2007-12-04 2017-10-24 Biogen Chesapeake Llc Formulaciones y procedimientos mejorados para liofilización y liofilizados obtenidos por los mismos
US20110034560A1 (en) * 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
AU2009266953A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Isoindolone derivatives as MEK kinase inhibitors and methods of use
MX2010014559A (es) 2008-07-01 2011-03-04 Genentech Inc Heterociclos bicíclicos sustituidos y metodos de uso.
RU2013115395A (ru) 2010-09-07 2014-10-20 СНУ Ар энд ДиБи ФАУНДЕЙШН Сестертерпеновое соединение и его применение
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
CN109069461A (zh) 2016-01-11 2018-12-21 洛克菲勒大学 与髓源性抑制细胞相关的病症的治疗方法
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
KR200492570Y1 (ko) 2018-12-04 2020-11-05 박규환 조립식 계단장치를 위한 발판
AU2020401286A1 (en) 2019-12-13 2022-06-23 Inspirna, Inc. Metal salts and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6111699A (en) * 1998-10-08 2000-05-01 Smithkline Beecham Plc Novel method and compounds
EP1212065A4 (en) * 1999-07-08 2004-02-11 Tularik Inc COMPILATIONS AND METHODS FOR INCREASING THE HDL CHOLESTEROL LEVEL

Also Published As

Publication number Publication date
EP1646625B1 (en) 2008-07-02
CO5640134A2 (es) 2006-05-31
UY28407A1 (es) 2005-02-28
KR20060034284A (ko) 2006-04-21
IL172759A0 (en) 2006-04-10
GB0316237D0 (en) 2003-08-13
CA2532068A1 (en) 2005-01-20
ES2308205T3 (es) 2008-12-01
CN1820003A (zh) 2006-08-16
AU2004256000A1 (en) 2005-01-20
WO2005005416A1 (en) 2005-01-20
NO20060080L (no) 2006-02-08
CN100478340C (zh) 2009-04-15
US20060189663A1 (en) 2006-08-24
UA82108C2 (ru) 2008-03-11
IS8291A (is) 2006-02-09
ZA200600229B (en) 2007-04-25
TW200507836A (en) 2005-03-01
JP2007521313A (ja) 2007-08-02
EP1646625A1 (en) 2006-04-19
DE602004014772D1 (de) 2008-08-14
RU2006102129A (ru) 2006-08-27
AR045720A1 (es) 2005-11-09
MXPA06000447A (es) 2006-04-07
SA04250203B1 (ar) 2008-02-25
ATE399776T1 (de) 2008-07-15
AU2004256000B2 (en) 2007-07-26
BRPI0412479A (pt) 2006-09-19

Similar Documents

Publication Publication Date Title
IL172759A0 (en) Pyrrole-2,5-dithione derivatives as liver x receptor modulators
IL172760A0 (en) Pyrrole-2,5-dithione derivatives as liver x receptor modulators
IL177218A0 (en) 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators
IL178767A0 (en) Indolyl derivatives as liver - x - receptor modulators
HK1092143A1 (en) Thiazole derivatives as cannabinoid receptor modulators
ZA200606974B (en) Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
EP1773768B8 (en) Pyrrole derivatives as pharmaceutical agents
HK1088003A1 (en) 3-substituted 5,6-diaryl-pyrazine-2-carboxamide and-2-sulfonamide derivatives as cb1 modulators
EP1581217A4 (en) CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF THE ANDROGEN RECEPTOR
EP1684762A4 (en) UREA DERIVATIVES AS MODULATORS OF KINASE
EP1790650B1 (en) NEW SUBSTITUTED IMIDAZOLE DERIVATIVES
GB0400440D0 (en) Receptor modulators
AU2003259482A1 (en) N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
ZA200609234B (en) Substituted azeplne derivatives as serotonin receptor modulators
IL183140A0 (en) Substituted benzoquinolizine derivatives
ZA200506744B (en) PyrazoloÄ1,5-AÜpyrimidine derivatives
EP1670483A4 (en) 17-heterocyclic 4-azasteroid derivatives as androgen receptor modules
SG121943A1 (en) Compositions for multi-color, light activated imaging
IL182739A0 (en) Acylatednonadepsipeptides used as lysobactin derivatives
PL1638940T3 (pl) Pochodne pirolidyniowe jako ligandy dla receptora muskarynowego M3
EP1663228A4 (en) USE OF 17-HETEROCYCLIC-4-AZASTEROIDIAN DERIVATIVES AS MODULATORS OF THE ANDROGEN RECEPTOR
AU2003301299A1 (en) Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators
AP2501A (en) Substituted pyrrole derivatives
IL173337A0 (en) Receptor
EP1641464A4 (en) 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS MODULATORS OF THE ANDROGEN RECEPTOR

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120708